• FirefoxUpgrade to the new Firefox »
  •  Dow Up 2.43% Nasdaq Up 2.24%

    Theravance Inc. (THRX)

    -NasdaqGS
    15.23 0.91(6.32%) Dec 18, 4:00PM EST
    Add to Portfolio
    Prev Close:14.32
    Open:14.47
    Bid:13.60 x 600
    Ask:200,000.00 x 100
    1y Target Est:24.71
    Beta:1.15
    Earnings Date:Feb 4 - Feb 9 (Est.)
    Day's Range:14.08 - 15.34
    52wk Range:12.56 - 32.89
    Volume:1,597,146
    Avg Vol (3m):1,044,980
    Market Cap:1.76B
    P/E (ttm):N/A
    EPS (ttm):-1.83
    Div & Yield:0.50 (3.80%)
    Quotes delayed, except where indicated otherwise. Currency in USD.

    Comparison

    Symbol% ChgMkt Cap
    THRXUp 6.32%1.76B
    AZN91.07B
    CBST7.46B
    PFE201.43B

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):579.27
    Ex-Dividend Date:21-Nov-14

    Analysts

    Annual EPS Est (Dec-14) :-1.42
    Quarterly EPS Est (Dec-14) :-0.12
    Mean Recommendation*:3.0
    PEG Ratio (5 yr expected):0.05

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and ... View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback